Innate Pharma SA Net Foreign Exchange Loss
Innate Pharma SA (IPHA) reported Net Foreign Exchange Loss of EUR 2.68 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:NetForeignExchangeLoss · last filed 2026-04-01
| Period end | Net Foreign Exchange Loss 6 month | Net Foreign Exchange Loss 12 month |
|---|---|---|
| 2025-12-31 | 2.68M EUR 20-F · filed 2026-04-01 | |
| 2024-12-31 | 3.41M EUR 20-F · filed 2026-04-01 | |
| 2024-06-30 | 1.76M EUR 6-K · filed 2024-09-12 | |
| 2023-12-31 | 1.20M EUR 20-F · filed 2026-04-01 | |
| 2023-06-30 | 642.00K EUR 6-K · filed 2024-09-12 | |
| 2022-12-31 | 2.98M EUR 20-F · filed 2025-04-30 | |
| 2022-06-30 | 3.66M EUR 6-K · filed 2023-09-14 | |
| 2021-12-31 | 3.59M EUR 20-F · filed 2024-04-04 | |
| 2021-06-30 | 1.60M EUR 6-K · filed 2022-09-15 | |
| 2020-12-31 | 5.56M EUR 20-F · filed 2023-04-06 | |
| 2020-06-30 | 1.54M EUR 6-K · filed 2021-09-15 | |
| 2019-12-31 | 4.77M EUR 20-F · filed 2022-04-04 | |
| 2018-12-31 | 3.85M EUR 20-F · filed 2021-04-27 | |
| 2017-12-31 | 6.66M EUR 20-F · filed 2020-04-24 |